The short version of Heptapeptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-30 and is reviewed periodically as new material appears.
Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.
Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.
Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
| Property | Value | Notes |
|---|---|---|
| Solid storage temperature | -20 °C or below | Desiccated and protected from light |
| Solution storage temperature | -80 °C as single-use aliquots | Avoid repeated freeze-thaw cycles |
| Purity assessment method | RP-HPLC, around 214 nm | Reported as main-peak area percent |
| Identity confirmation method | ESI-MS or MALDI-TOF | Measured mass compared with calculated mass |
| Common synonyms | ACTH(4-10) analog; Met-Glu-His-Phe-Pro-Gly-Pro | Also written as Semaxum in some sources |
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.
研究兴趣主要集中在神经营养因子相关的路径上，包括脑源性神经营养因子与神经生长因子的表达变化。部分实验报告称在特定条件下观察到这些因子的水平上升，但具体信号通路和剂量依赖关系仍未完全厘清。多数公开数据来自细胞模型和动物实验，人体对照研究数量有限。因此，该化合物的作用机制在文献中属于活跃讨论，而非已经确立的定论。
Semax 是一种人工合成的七肽，氨基酸序列为 Met-Glu-His-Phe-Pro-Gly-Pro，单字母缩写记作 MEHFPGP。它被归类为促肾上腺皮质激素片段 ACTH(4-10) 的结构类似物，但并不天然存在于生物体内。母体片段 ACTH(4-10) 的序列为 Met-Glu-His-Phe-Arg-Trp-Gly，Semax 替换了中间两个残基，并在羧基端延长了 Pro-Gly-Pro 三肽。这种延长被普遍认为能提升分子对肽酶的耐受性。
该化合物于二十世纪八十年代在俄罗斯被开发，相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性，而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示，这一方向促成了多个相关短肽的合成与筛选，而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。
=== 11 December === Ukrainian President Volodymyr Zelenskyy said that Russian forces have turned the city of Bakhmut into "burned ruins". The Ukrainians killed up to 60 and injured nearly 100 Russian soldiers near Kadiivka, Luhansk Oblast. They also killed 150 Russian soldiers and destroyed 10 pieces of equipment during strikes in Zaporizhzhia Oblast.
Red blood cells deliver oxygen from the lungs to the tissues and on their return carry carbon dioxide back to the lungs where it is exhaled. These functions are mediated by the cells' hemoglobin. The analyzer counts red blood cells, reporting the result in units of 106 cells per microlitre of blood (× 106/μL) or 1012 cells per litre (× 1012/L), and measures their average size, which is called the mean cell volume and expressed in femtolitres or cubic micrometres. By multiplying the mean cell volume by the red blood cell count, the hematocrit (HCT) or packed cell volume (PCV), a measurement of the percentage of blood that is made up of red blood cells, can be derived; and when the hematocrit is performed directly, the mean cell volume may be calculated from the hematocrit and red blood cell count. Hemoglobin, measured after the red blood cells are lysed, is usually reported in units of grams per litre (g/L) or grams per decilitre (g/dL). Assuming that the red blood cells are normal, there is a constant relationship between hemoglobin and hematocrit: the hematocrit percentage is approximately three times greater than the hemoglobin value in g/dL, plus or minus three. This relationship, called the rule of three, can be used to confirm that CBC results are correct. Two other measurements are calculated from the red blood cell count, the hemoglobin concentration, and the hematocrit: the mean corpuscular hemoglobin and the mean corpuscular hemoglobin concentration. These parameters describe the hemoglobin content of each red blood cell.
Iphigenia Photaki (Greek: Ιφιγένεια Φωτάκη, pronounced [ifiˈʝeni.a foˈtaki]; also known after marriage as Iphigenia Vourvidou-Photaki, Greek: Ιφιγένεια Βουρβίδου-Φωτάκη; 1921–1983) was a Greek organic chemist remembered for her contributions in peptide chemical synthesis, especially in the synthesis of biologically/enzymatically active peptides. Photaki was in 1965 the fourth woman overall to be habilitated in a scientific discipline in Greece, and the second to do so in the field of Chemistry. She specialised in peptide synthesis, influenced by her mentor and doctoral advisor Leonidas Zervas, a global authority on the subject. After distinguished research in Basel, Athens, and later Cornell, Photaki eventually rose to Professor of Organic Chemistry and Head of the Laboratory of Organic Chemistry of the University of Athens.
Sources: en.wikipedia.org
== Reaction mechanism == The side-chain amino group of ornithine (Orn) attacks the carbonyl carbon of carbamoylphosphate (CP), forming a tetrahedral intermediate. Collapse of the transitions state releases citrulline (Cit) and inorganic phosphate (Pi).
Lockheed implemented it into the L-1011 TriStar in 1973 at the request of Pacific Southwest Airlines (who used the baggage compartment as an entertainment lounge) and possibly also to suit potential Soviet buyers (see below). In October 1967, the Soviet government approved a Ministry of Civil Aviation (Aeroflot) specification for an aerobus. This called for 350 seats and a range of 3,600 kilometres (1,900 nautical miles) with a 40-tonne payload or 5,800 km (3,100 nmi) with seats taken but no freight. The airliner had to operate from smaller airports (classified as Klass "B" and "V" [Russian: класс "Б", "В"] or "Class B/C" by the Soviets) 2,600-metre (8,500 ft) runways. In the second half of the 1960s, OKB-240 (as the Ilyushin bureau was formally known) was restoring positions lost (with Yakovlev, in favour of Tupolev and Antonov) during the Khrushchev era and was well placed to secure design of the aerobus. When the Soviet cabinet's defence industry committee promoted the Aeroflot specification on September 8, 1969, to a preliminary project, (Russian: аванпроект; transliterated: avanproyekt), it entrusted it to Ilyushin. The bureau received specific operational requirements for the aerobus on February 22, 1970. In developing the concept which had been agreed, Ilyushin faced four challenges: configuration (layout or "shape"), powerplant, automation (avionics) and manufacturing capacity.
A catch bond is a type of noncovalent bond whose dissociation lifetime increases with tensile force applied to the bond. Normally, bond lifetimes are expected to diminish with force. In the case of catch bonds, the lifetime of the bond actually increases up to a maximum before it decreases like in a normal bond. Catch bonds work in a way that is conceptually similar to that of a Chinese finger trap. While catch bonds are strengthened by an increase in force, the force increase is not necessary for the bond to work. Catch bonds were suspected for many years to play a role in the rolling of leukocytes, being strong enough to roll in presence of high forces caused by high shear stresses, while avoiding getting stuck in capillaries where the fluid flow, and therefore shear stress, is low. The existence of catch bonds was debated for many years until strong evidence of their existence was found in bacteria. Definite proof of their existence came shortly thereafter in leukocytes.
== Description == Adults measure around 3 cm (1.2 in) in length. Adult males are a brownish orange or red, are slender, and have long, yellowish wings which allow it to attract females and to glide. Adult females are dark brown to black, with cream-colored markings on the shield and a cream-colored stripe edging its wings; they are broader than males, and have short vestigial wings. The ootheca is 9–12 mm (0.35–0.47 in) long, and it takes about 118–137 days for the eggs to hatch into nymphs. Nymphs are brown in front, black on the rear, and are wingless.
Sources: en.wikipedia.org
Each freeze-thaw cycle can degrade a fraction of the peptide and promote aggregation. Dividing a stock solution into single-use volumes removes repeated cycling as a variable. It also limits the time a thawed solution spends at room temperature.
A high main-peak percentage says little about identity, counter-ion content, or residual solvents. It also does not distinguish an isomer or a closely eluting analog. Mass confirmation and the accompanying documentation cover those gaps.
Salt form changes mass, solubility, and hygroscopicity, and acetate and trifluoroacetate salts behave differently in solution. Storage guidance still centers on -20 °C for powder and lower temperatures for solutions. The certificate should state which salt is present.
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.